Skip to content

TECO Aspergillus Galactomannan Assay 

Key Features


Detection of Aspergillus galactomannan antigen for the diagnosis of Invasive Aspergillosis (IA)


Product Description



The mortality rate of Invasive Aspergillosis is between 60 and 100% without timely treatment, thus reliable determination of galactomannan antigen may be essential.

  • Sandwich ELISA as diagnostic gold standard
  • Validated for serum and BAL samples
  • Significantly simplified sample preparation
  • Only 150 µL sample volume required
  • Limit of detection: 0.67 ng/ml (serum); 1.09 ng/ml (BAL)
  • Automation possible from sample to final result

Detection of galactomannan antigens as indicators of Aspergillus spec. infection using anti-galactomannan monoclonal antibodies and HRP-mediated color reaction. Established diagnostic procedure, significantly simplified sample preparation.


Request Quotation


Product
SKU
Pack Size
Qty
TECO Aspergillus Galactomannan Assay
SKU
TE1067
Pack Size
96 tests

Request Documentation


TECO Aspergillus Galactomannan Assay
TE1067

Associated Products



Latest News


Meet Us At BioMedica!

Endopredict, a NICE-recommended in-vitro diagnostic test for determining the prognosis and treatment response of breast cancer.

The 2024 Emissions Report

As part of our commitment to sustainability, we partner with DHL to cut transport related emissions. Details available in our new 2024 Emissions Report!

New Brand to reflect growth, innovation, and a unified vision to become a leading global Specialty Diagnostics company

We are happy to announce that Eurobio Scientific UK will undertake a brand update to align with the evolving structure of the Eurobio Scientific Group.

This new brand embodies the collective strengths of all our affiliates, combining expertise and resources to create synergies to enhance our product offerings.

Navigating ER+ HER2- Early Breast Cancer

November 19, 2024 - Join us for the first seminar in our new series!

“Navigating ER+ HER2- Early Breast Cancer”

The session “What's new for high-risk early breast cancer patients” will focus on CDK4/6 inhibitors in the adjuvant setting for high-risk breast cancer patients, featuring a real-life case discussion and insights into the potential role of gene expression tests, including prospective validation data in high- risk patients (UNIRAD).

Contact Us